Full Press Release Details
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista.
LXRX
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Key Takeaway: Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
Price reaction · baseline $1.68 (2024-08-20 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close · peak
+13.7%
day 1
+8.9%
day 3
+5.4%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus